These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23715066)

  • 1. Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data.
    Halpern R; Nadkarni A; Kalsekar I; Nguyen H; Song R; Baker RA; Nelson JC
    Ann Pharmacother; 2013; 47(7-8):933-45. PubMed ID: 23715066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
    Jing Y; Kalsekar I; Curkendall SM; Carls GS; Bagalman E; Forbes RA; Hebden T; Thase ME
    Clin Ther; 2011 Sep; 33(9):1246-57. PubMed ID: 21840058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y; Kim E; You M; Pikalov A; Tran QV
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.
    Kim E; You M; Pikalov A; Van-Tran Q; Jing Y
    BMC Psychiatry; 2011 Jan; 11():6. PubMed ID: 21214937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy.
    Nadkarni A; Kalsekar I; You M; Forbes R; Hebden T
    Clinicoecon Outcomes Res; 2013; 5():49-57. PubMed ID: 23378778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.
    Kim E; Maclean R; Ammerman D; Jing Y; Pikalov A; You M; Van-Tran Q; L'Italien G
    Clin Ther; 2009 Apr; 31(4):836-48. PubMed ID: 19446157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
    Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
    Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics.
    Bergeson JG; Kalsekar I; Jing Y; You M; Forbes RA; Hebden T
    Am Health Drug Benefits; 2012 Sep; 5(6):379-86. PubMed ID: 24991334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
    Wade RL; Kindermann SL; Hou Q; Thase ME
    J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
    Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
    Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
    Jing Y; Johnston SS; Fowler R; Bates JA; Forbes RA; Hebden T
    J Med Econ; 2011; 14(6):777-86. PubMed ID: 21954966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study.
    Kadakia A; Dembek C; Liu Y; Dieyi C; Williams GR
    J Med Econ; 2021; 24(1):1212-1220. PubMed ID: 34647502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating the Impact of Adherence to and Persistence with Atypical Antipsychotic Therapy on Health Care Costs and Risk of Hospitalization.
    Jiang Y; Ni W
    Pharmacotherapy; 2015 Sep; 35(9):813-22. PubMed ID: 26406773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data.
    Niu X; Dennen S; Dembek C; Laubmeier K; Liu Y; Veeranki P; Tocco M; Williams GR
    Curr Ther Res Clin Exp; 2021; 94():100629. PubMed ID: 34306269
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
    Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
    Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS; Greene M; Yan T; Chang E; Hartry A; Yermilov I
    Clin Ther; 2019 Feb; 41(2):221-232. PubMed ID: 30616973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL; Long SR; Chang S; Able S; Baser O; Obenchain RL; Swindle RW
    J Manag Care Pharm; 2006; 12(1):43-54. PubMed ID: 16420107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.